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attitudes of physicians in Germany towards telemonitoring. Methods: In the first 
step fundamental determinants of adoption and acceptance were identified using 
a systematic literature review and transferred to a theoretical effect model. This 
model was used to create a quantitative questionnaire which was then used to 
interview online 201 outpatient and inpatient physicians from different fields of 
medicine. The participants (84.3% male, mean age 53 years) were asked to assess the 
empirically based economic attributes of telemonitoring regarding its implementa-
tion. Results: The results show a lack of information regarding the financial risks 
of using telemedical technology, as only 14% of those interviewed said they felt 
sufficiently informed about the subject. Barriers to using telemedicine technology 
include missing arrangements for reimbursement, uncertain financial advantages 
and missing business models. In addition, the cost of implementation are indistinct 
for a broad majority of interviewees. On the other hand, in most queried dimension 
the user see a potential financial benefit due to telemedicine. The positive effects 
expected from telemonitoring were rated much better rated by those who already 
used telemonitoring in their professional life. ConClusions: In addition to a more 
precise legal framework, information security and quality-based guidelines, more 
emphasis must be placed on economic issues. It is also imperative that physicians 
be better informed about all aspects of telemedicine.
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objeCtives: In Germany, the AMNOG law replaced free pricing by the early ben-
efit assessment (EBA) since 2011. Manufacturers are free to set new drugs’ prices 
for up to one year after which the price is negotiated between manufacturers 
and insurers based on the EBA. The negotiated price, that is consistently lower 
than the one set by the manufacturers, is considered as the official list price since 
April 1st2014. The objective of this study is to evaluate the potential impact of this 
new law on the external reference pricing (ERP) in Europe. Methods: A simula-
tion model, developed for the European Commission, was used to simulate ERP’s 
impact on Boceprevir and Telaprevir prices after five years, following the discount’s 
inclusion on the official list price in Germany. ERP impact on price was evaluated 
in Belgium, Czech Republic, France, Germany, Luxembourg, Norway, Slovakia, 
Slovenia, Sweden, Switzerland, The Netherlands and UK for Boceprevir and in 
Belgium, Finland, France, Germany, Luxembourg, Norway, Poland, Slovakia, Slovenia, 
Sweden, Switzerland, The Netherlands and UK for Telaprevir. National policy inputs 
were obtained from a literature review and consultation of international organisa-
tions’ representatives. Prices used at the start of the simulation were obtained from 
IMS. Results: After five years, the relative price variation of Boceprevir between 
the scenario with AMNOG discount integrated in the list price and with no dis-
count integrated in the list price was null in Belgium, Luxembourg, Sweden and 
UK, of -8.1% in the Netherlands, -9.2% in Norway, nearly -10% in Czech Republic, 
France, Slovakia and Switzerland, and -14% in Slovenia. For Telaprevir, the price 
variation was null in Belgium, Finland, Luxembourg, Slovenia and the UK, of -0.8% 
in Slovakia, -2.5% in the Netherlands, -2.9% in Norway, -6.9% in France and -8.6% in 
Switzerland. ConClusions: Integrating AMNOG discount in the list price impacts 
significantly the price in European countries due to ERP.
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objeCtives: To investigate the adequacy of the widely used Cobb-Douglas 
and translog models of the production functions of hospital in-patient ser-
vices. Methods: To investigate the adequacy of the widely used Cobb-Douglas 
and translog models of the production functions of hospital in-patient services, 
we fitted these and additive models (AMs) to 2002-2007 data for the gynaecology 
and obstetrics, general and digestive surgery, internal medicine, and traumatol-
ogy and orthopaedic surgery services of 10 public hospitals in Galicia (NW Spain). 
Production, measured as admissions weighted in accordance with their diagnosis-
related groups (DRGs), was treated as a function of physician full-time equivalents 
as surrogate labour factor and number of beds as surrogate capital factor. Results: 
For the General Surgery specialty the findings for the CD model indicate a better 
fit than those for the Translog and the AM, as it is shown by AIC value while R2 
(CD= 96.32, Translog= 96.30, AM= 98.30) prefers the flexible AM. This is a good exam-
ple of using AM as a tool for checking the behaviour of existing parametric models. 
In this case we can be confident with Cobb-Douglas estimations. Findings for the 
Internal Medicine specialty indicate responses for the CD (AIC= -17.789) seems to be 
more “robust” than those based on the AM (AIC= -13.113) and Translog (AIC= -15.939) 
models, R2 (CD= 95.88, Translog= 95.80, AM= 97.90) shows better fit for the AM regres-
sion model. ConClusions: Our results suggest that while the Cobb-Douglas and 
translog models suffice to represent the production functions of services with low 
average DRG weight, the greater flexibility of models such as AMs is required for 
services with higher average DRG weight.
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objeCtives: Sex differences in drug use have been demonstrated in several thera-
peutic area. However, there is a lack of overviews on sex differences of drug use in 
entire populations. The aim of this study was to describe difference in prevalence 
of drugs use in the entire population in Italy between men and women. Methods: 
We performed a cross-sectional study using 2012 data from the IMS LifeLink 
Treatment DynamicsTM LRx Database, an italian-based administrative database 
that includes all prescribed drugs that are reimbursed by the Italian National 
Healthcare System. Pharmacological groups accounting for > 90% of the total 
volume in Defined Daily Doses were considered. Crude and age adjusted differ-
ences in prevalence were calculated as risk ratios of women/men. Results: 31 
therapeutic categories were analyzed and there are significant differences for 30 
of them. The largest sex difference in prevalence was found for thyroid prepara-
tions that were more common in women (59.3/1000 women and 10.9/1000 men, 
respectively). This was followed by antiinflammatory and antirheumatic products 
(114.0/1000 women and 67.4/1000 men) and antidepressants (62.1/1000 women 
and 26.8/1000 men). The pharmacological groups with the largest relative differ-
ences of dispensed drugs were drugs affecting bone structure and mineralization 
(RR 12.4), calcium (RR 7.0) and thyroid therapy (RR 4.9), which were dispensed to 
women to a higher degree. Antigout-agents (RR 0.4), vasodilators used in cardiac 
diseases (RR 0.7) and ACE inhibitors (RR 0.7) were dispensed to men to a larger 
proportion. ConClusions: This is the first Italian study that shows substantial 
differences between men and women. Our findings are congruent with those 
reported previously in the literature. Some of differences may be explained by 
variations in disease prevalence and severity, pathophysiology, or by other biologi-
cal differences. However, it is also evident that other differences lack a rational 
medical explanation.
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objeCtives: The Human Capital Theory emphasizes investments to the health 
care sector as an important element in achieving and sustaining economic devel-
opment. Investments to health care sector improves macro and micro economic 
outcomes for the whole society. The aim of this study is to calculate the possible 
produced value for a life-time term (VLT) and cost of pre-mature deaths (CPD) 
from the productivity for USA, Canada, Japan and Australia. Methods: Net pre-
sent value (NPV) of the taxes and spending for each year were calculated. For 
calculating NPV in the government perspectives, two modelling approaches were 
combined, human capital modelling based on lives saved and lost productivity, 
and generational accounting, which accounts for a range of other government 
fiscal transfers to citizens. The possible produced value for a life-time term for 
each country were assumed as calculating the total NPV for each country depend-
ing on the countries life expectancy. CPD for each countries were assumed as the 
difference between NPV on the year of life expectancy and each decades as life 
years 60, 50, 40, 30, 20, 10. The economic values for the model of each country 
derived from World Bank, OECD, UNESCO or WHO. Results: Possible produced 
value for a life-time term for each country were calculated as US $ 1.415.530, US$ 
774.663, US$ 238.236 and US$ 2.917.835 for USA, Canada, Japan and Australia, 
respectively. CPD per person for USA were calculated as US$ -1.526.126, US$ 
-1.661.257, US$ -1.300.923, US$ -796.547, US$ - 351.827 and US$ -40.507 for the life 
years 10, 20, 30, 40, 50 and 60 respectively. The trend was same for Canada, Japan 
and Australia. ConClusions: However the study was based on a hypothetical 
model that calculated the NPV with the taxes and spending in a life-time term, 
the results of each country were parallel.
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objeCtives: Based on the content of drugs in households, it is possible to examine 
the inclination of patients towards self-medication and groups of drugs that are 
commonly used for this purpose. Taking into consideration the above, the present 
study aimed to investigate the self-medication practice, with an emphasis on 
self-medication with prescription only medications. Methods: The study was 
performed in 8 months period and involved 383 randomly selected households. 
The study consisted of a personal insight into the inventory of all drugs. The inter-
viewer recorded the total number of drugs in households and asked respondents 
for each the drug was obtained on prescription or bought in the pharmacy for 
self-medication. After the data were collected, drugs were classified according the 
Anatomical Therapeutic Chemical (ATC) Classification System. Drugs were also 
classified according to ALIMS (Medicines and Medical Devices Agency of Serbia) 
into two groups: prescription only medication (POM) and OTC (Over the Counter) 
drugs and then analyzed. Results: The total number of drug items present in 
the 383 households was 4384 with an average of 11.4±5.8 per household. More 
than a half of drugs in households were prescription only medications (58,5%). 
Approximately one third of these drugs were obtained without prescription. The 
most common prescription only medications obtained without prescription 
were anti-inflammatory and antirheumatic products (41,8%) and antibacterials 
for systemic use (12,4%). Ibuprofen (61,0%), diclofenac (27,8%) and nimesulide 
(8,2%) were the most common self-medicated drugs in the group of antiinflama-
tory drugs, while the most frequently self-medicated antibiotics were cefalexin 
(25,7%), doxyciclin (18,6%), cotrimoxazole (17,7%). ConClusions: In conclusion, 
our survey indicated that self-mediation with prescription drugs appeared to be 
a rather common practice, which is far away from the concept of “responsible 
self-medication”, especially regarding antibiotics. ACKnoWledGeMent: This 
work was supported by the Ministry of Science and Technological development, 
Republic of Serbia, project No. 41012.
A424  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
PHP118
PattErns anD PrEDictors of HosPital rEaDmission in taiWan
Cheng J.S.1, Ku H.P.1, Chang C.J.2
1Chang Gung University, Tao-Yuan, Taiwan, 2Chang Gung University, Kwei Shan, Tao Yuan, 
Taiwan
objeCtives: Hospital readmissions have been an important issue, as they reflect 
suboptimal quality of medical care and incur high health care expenditures. 
However, limited information is available on the patterns of hospital readmission 
in the entire population to support a thorough planning to prevent hospital readmis-
sions. Therefore, this study aimed to examine the patterns and economic burden 
of hospital readmission in Taiwan, and identify predictors of hospital readmis-
sions. Methods: This study used the National Health Insurance Research Database 
of enrollees randomly selected from those enrolled in the National Health Insurance 
program in 2005. Individuals who were admitted to acute hospitals in 2005 were 
selected and their readmission patterns one-year after discharge were examined. 
Cox proportional hazards regression model was adopted to identify predictors of 
hospital readmission. Results: The 30-day, 6-month and one-year readmission 
rates were 11%, 25%, and 34%, respectively. During the one-year follow-up, 52% of 
total health care expenditures were due to hospital readmissions. Of those who 
were readmitted to hospitals, 56% were readmitted once and took up 29% of the 
cost of rehospitalization. However, those readmitted for more than three times (5%) 
accounted for 30% of the cost. The major disease category of the highest 30-day and 
one-year readmission rates was neoplasms. The disease of the highest 30-day and 
one-year readmission rates were cancer of bronchus and lung (36%) and cancer of 
liver and intrahepatic bile duct (74%), respectively, and the most frequent reason 
for readmission was the disease itself. Age, gender, place of residence, previous 
hospitalization history, comorbidities, and length of stay of the index hospitalization 
were risk factors of hospital readmissions. ConClusions: This study identified 
diseases of higher short-term and long-term readmission rates, causes of short-
term and long-term hospital readmissions, and predictors of hospital readmission. 
The information is of importance for planning interventions to reduce hospital 
readmission rate.
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objeCtives: More than half of medication errors are reported during admin-
istration. “Smart” Infusion Safety Systems (SISS) have been developed to avoid 
administration errors and provide data for continuous quality improvement (CQI). 
Few data produced by SISS have been analysed. Given the lack of clinical trials, a 
model was developed in order to assess the economic benefits of SISS from the 
perspective of a French public hospital. Methods: Comprehensive data from 
6 intensive care units (ICU) were analysed. Two types of alerts were defined: hard 
(absolute) and soft limits. An avoided error was defined as the detection of a 
scheduled infusion over a hard limit or a scheduled infusion over a soft limit that 
was later overridden by staff. The severity of consequences was estimated on 
the HARM INDEX score, which is based on the pharmacologic risk, overdose 
detectability, overdosing range and the type of hospital unit. According to this 
score, errors were categorised as minor, significant, and serious. The economic 
value was estimated based on the hypothetical resulting length of stay had the 
error not been avoided, which increases according to error severity, and the 
financial investment for SISS. Results: Overall, 207,025 infusions were analysed 
from the database of 6 ICUs and 8,503 of them were associated with a safety 
alert (4.1%), including 987 errors (0.48%). Applied to one public ICU equipped with 
5 SISS, the model estimates that SISS would prevent 78 errors per year (54 minor, 
12 significant, 12 serious) and avoid 173 days of hospitalisation per year. This 
corresponds to an annual savings of € 139,491 for the hospital (39% and 61% from 
significant and serious errors, respectively). ConClusions: This model demon-
strates the high economic burden of medication errors for French public hospitals 
and the need for CQI. To date, no equivalent evaluation has been conducted in 
France.
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objeCtives: The Human Capital Theory emphasizes investments to the health 
care sector as an important element in achieving and sustaining economic devel-
opment. Investments to health care sector improves macro and micro economic 
outcomes for the whole society. The aim of this study is to calculate the possible 
produced value for a life-time term (VLT) and cost of pre-mature deaths (CPD) 
from the productivity for France, Germany, Italy, Spain, UK (UK). Methods: Net 
present value (NPV) of the taxes and spending for each year were calculated. For 
calculating NPV in the government perspectives, two modelling approaches were 
combined, human capital modelling based on lives saved and lost productivity, 
and generational accounting, which accounts for a range of other government fis-
cal transfers to citizens. The possible produced value for a life-time term for each 
country were assumed as calculating the total NPV for each country depending 
on the countries life expectancy. CPD for each countries were assumed as the dif-
ference between NPV on the year of life expectancy and each decades as life years 
60, 50, 40, 30, 20, 10. The economic values for the model of each country derived 
from World Bank, OECD, UNESCO or WHO. Results: Possible produced VLT term 
for each country were calculated as US$ 993.347, US$ 629.814, US$ 245.885, US$ 
48.818 and US$ 1.628.957 for France, Germany, Italy, Spain, UK, respectively. CPD per 
person for France were calculated as US$ -1.060.571, US$ -1.148.852, US$ -887.348, 
US$ -551.873, US$ - 224.070 and US$ -10.972 for the life years 10, 20, 30, 40, 50 and 60 
respectively. Although numbers were different, the trend was same for Germany, 
Italy, Spain, UK. ConClusions: However the study was based on a hypothetical 
model that calculated the NPV with the taxes and spending in a life-time term, 
the results of each country were parallel.
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objeCtives: Lifelong immunoglobulin G (IgG) replacement is the standard ther-
apy for patients with primary antibody deficiencies. It can be administered either 
intravenously (IVIg) by health care providers in hospital or subcutaneously (SCIg) 
by patients at home. However, self-administration requires patients’ education 
and support over long term to ensure proper adherence and optimal efficacy and 
safety. Every patient who switches to SCIg is proposed by the Policlinique Médicale 
Universitaire (Lausanne, Switzerland) a drug therapy management program with a 
nurse and a community pharmacist including training, coaching and follow-up. 
The aim of the study was to evaluate if switching to SCIg at home including the 
management program was cost-effective compared to IVIg at hospital. Methods: 
Assuming that both therapies provide similar efficacy, a 3-years cost-minimization 
analysis based on a simulation model was performed from a societal perspective. 
Health care costs (IgG, time of professionals, infusion pumps and disposables) were 
derived from administrative data. Transport and losses of productivity were esti-
mated. One-way sensitivity analyses were performed. Results: Under base case 
assumptions, SCIg at home was estimated at 34960 CHF per patient the first year 
and 30 030 CHF in subsequent years against 34 170 CHF per year for IVIg. The total 
savings for a switch to SCIg at home with the program was 7490 CHF per patient over 
3 years. Results were relatively sensible to the assumptions. ConClusions: Home-
based SCIg therapy including an interprofessional therapy management program 
may be an effective and efficient alternative to hospital for patients with primary 
antibody deficiencies. Additional costs from purchase of equipment and manage-
ment program in the first year were offset by hospital costs avoided in short term. 
Additional studies are ongoing to analyse the retention in the therapy in medium 
term and the impact on quality of life.
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objeCtives: Personalized medicine is currently a popular topic in health care 
debates. Yet, the basic differentiation between females and males is hardly found 
in care delivery/health management programs. This study aimed at elucidating 
the opinion of German Statutory Health Insurance (SHI) managers and internal 
specialists regarding gender-specific care in order to understand their percep-
tions on responsibilities and possible implementation opportunities. Methods: 
Between April and June 2013, a questionnaire on the implementation of gender 
medicine in the current health care landscape was developed. Based on literature 
review and expert consultations, it included open- and closed-ended questions on 
expectations/prioritization, need for action, and implementation of gender medi-
cine. Forty-eight insurance managers of the largest German SHIs, covering over 
95% of the market, and approximately 16,000 physicians of the German Society 
for Internal Medicine (DGIM) were contacted to complete a web-based survey. 
Descriptive analyses, Chi-square tests, and Pearson correlation coefficient were 
used to investigate the research objective. Results: According to both, insurance 
managers (76%) and physicians (60%), gender-specific care is not sufficiently incor-
porated into standard medical care. Respondents claim the responsibility lies with 
the ministry of health, physicians and medical staff, as well as their associations. 
Specifically, more evidence is needed to incorporate gender aspects in treatment 
guidelines, an idea which is well-supported by insurances (65%) and physicians 
(70%). A top-down approach for implementation is preferred by 65% of insurance 
managers and 50% of physicians, whereas fewer participants encourage bottom-
up mechanisms. ConClusions: German SHIs expect a significant governmental 
influence and/or support of self-governing bodies to achieve an incorporation of 
gender medicine into daily practice. Primary responsibility for the integration of 
gender-specific approaches is perceived to lie with physicians. As soon as critical 
hurdles in the medical field will be removed, the positive perception of both partici-
pating parties can be integrated in the implementation process of gender-medicine.
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objeCtives: The Human Capital Theory emphasizes investments to the health 
care sector as an important element in achieving and sustaining economic 
development. Investments to health care sector improves macro and micro eco-
nomic outcomes for the whole society. The aim of this study is to calculate the 
possible produced value for a life-time term (VLT) and cost of pre-mature deaths 
(CPD) from the productivity for Turkey where the life expectancies was noted 75 
years. Methods: Net present value (NPV) of the taxes and spending for each year 
were calculated. For calculating NPV in the government perspectives, two modeling 
approaches were combined, human capital modeling based on lives saved and lost 
